Glutamate and GABA-Metabolizing Enzymes in Post-mortem Cerebellum in Alzheimer’s Disease: Phosphate-Activated Glutaminase and Glutamic Acid Decarboxylase

Cerebellum

Volumn 13, Issue 5, 2014, Pages 607-615

  Burbaeva, G Sh ^a   Boksha, I S ^a   Tereshkina, E B ^a   Savushkina, O K ^a   Prokhorova, T A ^a   Vorobyeva, E A ^a  

^a MENTAL HEALTH RESEARCH CENTER   (Russian Federation)

Author keywords

Alzheimer s disease; Autopsied cerebellum; GABA metabolism; Glutamate metabolism; Glutamic acid decarboxylase; Phosphate activated glutaminase

Indexed keywords

4 AMINOBUTYRIC ACID; AMIDE SYNTHASE; GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE 1; GLUTAMATE DECARBOXYLASE 2; GLUTAMATE DEHYDROGENASE; GLUTAMIC ACID; GLUTAMINASE; GLUTAMINE SYNTHETASE-LIKE PROTEIN, HUMAN; NERVE PROTEIN;

AGED; ALZHEIMER DISEASE; CEREBELLUM; COMPARATIVE STUDY; ENZYMOLOGY; HUMAN; METABOLISM; MIDDLE AGED; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMIDE SYNTHASES; CEREBELLUM; GAMMA-AMINOBUTYRIC ACID; GLUTAMATE DECARBOXYLASE; GLUTAMATE DEHYDROGENASE; GLUTAMIC ACID; GLUTAMINASE; HUMANS; MIDDLE AGED; NERVE TISSUE PROTEINS;

EID: 84929505223     PISSN: 14734222     EISSN: 14734230     Source Type: Journal    
DOI: 10.1007/s12311-014-0573-4     Document Type: Article

References (65)

1. Fujiwara T, Morimoto K. A compound CP-31398 suppresses excitotoxicity-induced neurodegeneration. Biochem Biophys Res Commun. 2013;440(3):359–63.
2. Hoey SE, Buonocore F, Cox CJ, Hammond VJ, Perkinton MS, Williams RJ. AMPA receptor activation promotes non-amyloidogenic amyloid precursor protein processing and suppresses neuronal amyloid-β production. PLoS One. 2013;8(10):e78155. doi:10.1371/journal.pone.0078155.
3. Wang ZC, Zhao J, Li S. Dysregulation of synaptic and extrasynaptic N-methyl-D-aspartate receptors induced by amyloid-β. Neurosci Bull. 2013;29(6):752–60.
4. Majláth Z, Toldi J, Vécsei L. The potential role of kynurenines in Alzheimer’s disease: pathomechanism and therapeutic possibilities by influencing the glutamate receptors. J Neural Transm. 2013. doi:10.1007/s00702-013-1135-5.
5. Jones RS, Waldman AD. 1H-MRS evaluation of metabolism in Alzheimer’s disease and vascular dementia. Neurol Res. 2004;26(5):488–95.
6. Boksha IS. Coupling between neuronal and glial cells via glutamate metabolism in brain of healthy persons and patients with mental disorders. Biochemistry (Mosc). 2004;69(7):705–19.
7. Burbaeva GS, Boksha IS, Tereshkina EB, Savushkina OK, Starodubtseva LI, Turishcheva MS. Glutamate metabolizing enzymes in prefrontal cortex of Alzheimer’s disease patients. Neurochem Res. 2005;30(11):1443–51.
8. Olabarria M, Noristani HN, Verkhratsky A, Rodríguez JJ. Age-dependent decrease in glutamine synthetase expression in the hippocampal astroglia of the triple transgenic Alzheimer’s disease mouse model: mechanism for deficient glutamatergic transmission? Mol Neurodegener. 2011;6:55–63.
9. Adeva MM, Souto G, Blanco N, Donapetry C. Ammonium metabolism in humans. Metabolism. 2012;61(11):1495–511.
10. Albrecht J, Norenberg MD. Glutamine: a Trojan horse in ammonia neurotoxicity. Hepatology. 2006;44(4):788–94.
11. Albrecht J, Sonnewald U, Waagepetersen HS, Schousboe A. Glutamine in the central nervous system: function and dysfunction. Front Biosci. 2007;1(12):332–43.
12. Bae N, Wang Y, Li L, Rayport S, Lubec G. Network of brain protein level changes in glutaminase deficient fetal mice. J Proteomics. 2013;27(80):236–49.
13. Dumanis SB, DiBattista AM, Miessau M, Moussa CE, Rebeck GW. APOE genotype affects the pre-synaptic compartment of glutamatergic nerve terminals. J Neurochem. 2013;124(1):4–14.
14. Vermeiren Y, Van Dam D, Aerts T, Engelborghs S, De Deyn PP. Brain region-specific monoaminergic correlates of neuropsychiatric symptoms in Alzheimer’s disease. J Alzheimer’s Dis. 2014 Mar 31.
15. O’Halloran CJ, Kinsella GJ, Storey E. The cerebellum and neuropsychological functioning: a critical review. J Clin Exp Neuropsychol. 2012;34(1):35–56.
16. Holten AT, Gundersen V. Glutamine as a precursor for transmitter glutamate, aspartate and GABA in the cerebellum: a role for phosphate-activated glutaminase. J Neurochem. 2008;104(4):1032–42.
17. Burbaeva GS, Savushkina OK, Dmitriev AD. Brain isoforms of creatine kinase in health and mental diseases: Alzheimer’s disease and schizophrenia. Vestn Ross Akad Med Nauk. 1999;1:20–4 [Russian].
18. Burbaeva GSh, Savushkina OK, Boksha IS. Comparative study of creatine kinase BB decrease in brain of patients with Alzheimer’s disease and schizophrenia. In: Kekelidze T, Holtzman D, editors. Creatine kinase and brain energy metabolism. NATO Science Series, 342, Netherlands: IOS Press; 2003. p. 125–132.
19. Burbaeva GS, Turishcheva MS, Vorobyeva EB, Savushkina OK, Tereshkina EB, Boksha IS. Diversity of glutamate dehydrogenase in human brain. Prog Neuropsyhopharmacol Biol Psychiatry. 2002;26(3):427–35.
20. Buddhala C, Suarez M, Modi J, Prentice H, Ma Z, Tao R, et al. Calpain cleavage of brain glutamic acid decarboxylase 65 is pathological and impairs GABA neurotransmission. PLoS One. 2012;7(3):e33002.
21. Kaneko T, Itoh K, Shigemoto R, Mizuno N. Glutaminase-like immunoreactivity in the lower brain stem and cerebellum of the adult rat. Neuroscience. 1989;32(1):79–98.
22. Levi G, Gallo V. Glutamate as a putative transmitter in the cerebellum: stimulation by GABA of glutamic acid release from specific pools. J Neurochem. 1981;37(1):22–31.
23. Kvamme E, Roberg B, Torgner IA. Phosphate-activated glutaminase and mitochondrial glutamine transport in the brain. Neurochem Res. 2000;25(9–10):1407–19.
24. Kvamme E, Torgner IA, Roberg B. Kinetics and localization of brain phosphate activated glutaminase. J Neurosci Res. 2001;66(5):951–8.
25. Roberg B, Torgner IA, Laake J, Takumi Y, Ottersen OP, Kvamme E. Properties and submitochondrial localization of pig and rat renal phosphate-activated glutaminase. Am J Physiol Cell Physiol. 2000;279(3):C648–57.
26. Kvamme E, Nissen-Meyer LS, Roberg BA, Torgner IA. Novel form of phosphate activated glutaminase in cultured astrocytes and human neuroblastoma cells, PAG in brain pathology and localization in the mitochondria. Neurochem Res. 2008;33(7):1341–5.
27. Shimmura C, Suzuki K, Iwata Y, Tsuchiya KJ, Ohno K, Matsuzaki H, et al. Enzymes in the glutamate glutamine cycle in the anterior cingulate cortex in postmortem brain of subjects with autism. Mol Autism. 2013;4(1):6–13.
28. Akiyama H, McGeer PL, Itagaki S, McGeer EG, Kaneko T. Loss of glutaminase-positive cortical neurons in Alzheimer’s disease. Neurochem Res. 1989;14(4):353–8.
29. Haug LS, Ostvold AC, Cowburn RF, Garlind A, Winblad B, Bogdanovich N, et al. Decreased inositol (1,4,5)-trisphosphate receptor levels in Alzheimer’s disease cerebral cortex: selectivity of changes and possible correlation to pathological severity. Neurodegeneration. 1996;5(2):169–76.
30. Lynn BC, Wang J, Markesbery WR, Lovell MA. Quantitative changes in the mitochondrial proteome from subjects with mild cognitive impairment, early stage and late stage Alzheimer’s disease. J Alzheimers Dis. 2010;19(1):325–39.
31. Monnerie H, Le Roux PD. Glutamate alteration of glutamic acid decarboxylase (GAD) in GABA ergic neurons: the role of cysteine proteases. Exp Neurol. 2008;213(1):145–53.
32. Turský T, Lassánová M. Inhibition of different molecular forms of brain glutamic acid decarboxylase (GAD) with ATP. J Neurochem. 1978;30(4):903–5.
33. Erlander MG, Tobin AJ. The structural and functional heterogeneity of glutamic acid decarboxylase: a review. Neurochem Res. 1991;16(3):215–26.
34. Esclapez M, Tillakaratne NJK, Kaufman DL, Tobin AJ, Houser CR. Comparative localization of two forms of glutamic acid decarboxylase and their mRNAs in rat brain supports the concept of functional differences between the forms. J Neurosci. 1994;14(3):1834–55.
35. Tian N, Petersen C, Kash S, Baekkeskov S, Copenhagen D, Nicoll R. The role of the synthetic enzyme GAD65 in the control of neuronal gamma-aminobutyric acid release. Proc Natl Acad Sci U S A. 1999;96:12911–6.
36. Wei J, Wu J-Y. Post-translational regulation of L-glutamic acid decarboxylase in the brain. Neurochem Res. 2008;33:1459–65.
37. Martin DL, Martin SB, Wu SJ, Espina N. Cofactor interactions and the regulation of glutamate decarboxylase activity. Neurochem Res. 1991;16(3):243–9.
38. Fenalti G, Law RH, Buckle AM, Langendorf C, Tuck K, Rosado CJ, et al. GABA production by glutamic acid decarboxylase is regulated by a dynamic catalytic loop. Nat Struct Mol Biol. 2007;14:280–6.
39. Kaufman DL, Houser CR, Tobin A. Two forms of the aminobutyric acid synthetic enzyme glutamate decarboxylase have distinct intraneuronal distribution and cofactor interaction. J Neurochem. 1991;56:720–3.
40. Owens D, Kriegstein A. Is there more to GABA than synaptic inhibition? Nat Rev Neurosci. 2002;3:715–27.
41. Asada H, Kawamura Y, Maruyama K. Mice lacking the 65 kDa isoform of glutamic acid decarboxylase (GAD65) maintain normal levels of GAD67 and GABA in their brains but are susceptible to seizures. Biochem Biophys Res Commun. 1996;229:891–5.
42. Asada H, Kawamura Y, Maruyama K. Cleft palate and decreased brain gamma-aminobutyric acid in mice lacking the 67-kDa isoform of glutamic acid decarboxylase. Proc Natl Acad Sci U S A. 1997;94(12):6496–9.
43. Schwab C, Yu S, Wong W, McGeer EG, McGeer PL. GAD65, GAD67, and GABAT immunostaining in human brain and apparent GAD65 loss in Alzheimer’s disease. J Alzheimers Dis. 2013;33(4):1073–88.
44. 2-terminal region of the 65-kDa isoform of glutamic acid decarboxylase. J Biol Chem. 1995;270:2241–6.
45. Kanaani J, Lissin D, Kash SF, Baekkeskov S. The hydrophilic isoform of glutamate decarboxylase, GAD67, is targeted to membranes and nerve terminals independent of dimerization with the hydrophobic membrane-anchored isoform, GAD65. J Biol Chem. 1999;274(52):37200–9.
46. Mitew S, Kirkcaldie MT, Dickson TC, Vickers JC. Altered synapses and gliotransmission in Alzheimer’s disease and AD model mice. Neurobiol Aging. 2013;34(10):2341–51.
47. Krantic S, Isorce N, Mechawar N, Davoli MA, Vignault E, Albuquerque M, et al. Hippocampal GABAergic neurons are susceptible to amyloid-β toxicity in vitro and are decreased in number in the Alzheimer’s disease TgCRND8 mouse model. J Alzheimers Dis. 2012;29(2):293–308.
48. Sjöbeck M, Englund E. Alzheimer’s disease and the cerebellum: a morphologic study on neuronal and glial changes. Dement Geriatr Cogn Disord. 2001;12(3):211–8.
49. Bowen DM, White P, Flack RH, Smith CB, Davison AN. Brain-decarboxylase activities as indices of pathological change in senile dementia. Lancet. 1974;1(7869):1247–9.
50. Reinikainen KJ, Paljärvi L, Huuskonen M, Soininen H, Laakso M, Riekkinen PJ. A postmortem study of noradrenergic, serotonergic and GABAergic neurons in Alzheimer’s disease. J Neurol Sci. 1988;84(1):101–16.
51. Boissière F, Faucheux B, Duyckaerts C, Hauw JJ, Agid Y, Hirsch EC. Striatal expression of glutamic acid decarboxylase gene in Alzheimer’s disease. J Neurochem. 1988;71(2):767.
52. Perry EK, Gibson PH, Blessed G, Perry RH, Tomlinson BE. Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue. J Neurol Sci. 1977;34(2):247–65.
53. Gluck MR, Thomas RG, Davis KL, Haroutunian V. Implications for altered glutamate and GABA metabolism in the dorsolateral prefrontal cortex of aged schizophrenic patients. Am J Psychiatry. 2002;159(7):1165–11673.
54. Yates CM, Butterworth J, Tennant MC, Gordon A. Enzyme activities in relation to pH and lactate in postmortem brain in Alzheimer-type and other dementias. J Neurochem. 1990;55(5):1624–30.
55. Monfort JC, Javoy-Agid F, Hauw JJ, Dubois B, Agid Y. Brain glutamate decarboxylase in Parkinson’s disease with particular reference to a premortem severity index. Brain. 1985;108(2):301–13.
56. Simpson MD, Cross AJ, Slater P, Deakin JF. Loss of cortical GABA uptake sites in Alzheimer’s disease. J Neural Transm. 1988;71(3):219–26.
57. Bland R, Fitzsimons H. Novel glutamic acid decarboxylase (GAD) chimera and methods of use. USA Patent US8071563 B2. 2009
58. Whitelaw BS, Robinson MB. Inhibitors of glutamate dehydrogenase block sodium-dependent glutamate uptake in rat brain membranes. Front Endocrinol (Lausanne). 2013;4:123.
59. Bauer DE, Jackson JG, Genda EN, Montoya MM, Yudkoff M, Robinson MB. The glutamate transporter, GLAST, participates in a macromolecular complex that supports glutamate metabolism. Neurochem Int. 2012;61(4):566–74.
60. Middleton FA, Strick PL. Cerebellar projections to the prefrontal cortex of the primate. J Neurosci. 2001;21(2):700–12.
61. Schmahmann JD. The role of the cerebellum in cognition and emotion: personal reflections since 1982 on the dysmetria of thought hypothesis, and its historical evolution from theory to therapy. Neuropsychol Rev. 2010;20(3):236–60.
62. Timmann D, Daum I. Cerebellar contributions to cognitive functions: a progress report after two decades of research. Cerebellum. 2007;6(3):159–62.
63. Arnsten AF, Rubia K. Neurobiological circuits regulating attention, cognitive control, motivation, and emotion: disruptions in neurodevelopmental psychiatric disorders. J Am Acad Child Adolesc Psychiatry. 2012;51(4):356–67.
64. Konarski JZ, McIntyre RS, Grupp LA, Kennedy SH. Is the cerebellum relevant in the circuitry of neuropsychiatric disorders? J Psychiatry Neurosci. 2005;30(3):178–86.
65. Chen J, Cohen ML, Lerner AJ, Yang Y, Herrup K. DNA damage and cell cycle event simplicate cerebellar dentate nucleus neurons as targets of Alzheimer’s disease. Mol Neurodegener. 2010;20(5):60–71.